Compare SHC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | AXSM |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | 3000 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 12.0B |
| IPO Year | 2020 | 2015 |
| Metric | SHC | AXSM |
|---|---|---|
| Price | $15.72 | $248.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $20.33 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.3M | 594.1K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | 38.56 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,163,617,000.00 | N/A |
| Revenue This Year | $7.51 | $57.24 |
| Revenue Next Year | $6.00 | $55.88 |
| P/E Ratio | $175.28 | ★ N/A |
| Revenue Growth | ★ 5.74 | N/A |
| 52 Week Low | $10.94 | $96.09 |
| 52 Week High | $19.85 | $260.19 |
| Indicator | SHC | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 67.86 |
| Support Level | $15.00 | $148.87 |
| Resistance Level | $16.47 | N/A |
| Average True Range (ATR) | 0.53 | 8.93 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 50.61 | 77.49 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.